Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension

Détails

ID Serval
serval:BIB_66177D0B866B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension
Périodique
Journal of the Renin-Angiotensin-Aldosterone System
Auteur(s)
Gojanovic B., Feihl F., Liaudet L., Waeber B.
ISSN
1470-3203
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
9
Numéro
1
Pages
1-9
Langue
anglais
Résumé
Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists (CAs) and blockers of the renin-angiotensin system [angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists (ARBs)] are widely used today to initiate antihypertensive treatment but, when given as monotherapy, do not suffice in most patients to normalise blood pressure (BP). Combining a CA and either an ACE-inhibitor or an ARB considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. Several fixed-dose combinations are available (CA + ACE-inhibitors: amlodipine + benazepril, felodipine + ramipril, verapamil + trandolapril; CA + ARB: amlodipine + valsartan). They are expected not only to improve BP control, but also to facilitate long-term adherence with antihypertensive therapy, thereby providing maximal protection against the cardiovascular and renal damage caused by high BP.
Mots-clé
administration & dosage , Adult , adverse effects , Aged , Angiotensin II , Angiotensin-Converting Enzyme Inhibitors , antagonists & inhibitors , Atenolol , blood , Blood Pressure , Calcium , Calcium Channel Blockers , complications , Drug Combinations , drug effects , drug therapy , Drug Therapy,Combination , Enzyme Inhibitors , Humans , Hypertension , Indoles , Middle Aged , Patients , Randomized Controlled Trials as Topic , Renin-Angiotensin System , Switzerland , Sympathetic Nervous System , therapeutic use , therapy , Verapamil
Pubmed
Web of science
Création de la notice
29/01/2009 23:13
Dernière modification de la notice
20/08/2019 15:22
Données d'usage